WallStSmart
SNGX

Soligenix Inc.

NASDAQ: SNGX · HEALTHCARE · BIOTECHNOLOGY

$0.35
+2.07% today

Updated 2026-04-30

Market cap
$4.34M
P/E ratio
P/S ratio
9.78x
EPS (TTM)
$-2.14
Dividend yield
52W range
$0 – $6
Volume
0.6M

Soligenix Inc. (SNGX) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
-152.7%
Last 4 quarters
Revenue YoY growth
Most recent quarter
EPS YoY growth
+74.8%
Most recent quarter

When is the next earnings report?

Reporting date
December 31, 2025
Consensus EPS estimate
$-0.27
Fiscal period ending
2025-12-31

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+4.9%
Last 2 reports
Positive reaction rate
100%
2 of 2 quarters
Largest single-day move
+6.3%
2025-11-07
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-31$-0.29$1.11$1.15+3.6%
2025-11-07$-0.58-383.3%$1.28$1.36+6.3%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2026-03-31$-0.29
2025-12-31$-0.27
2025-09-30$-0.12$-0.58-383.3%
2025-06-30$-0.11$-0.82-645.5%
2025-03-31$-0.67$-1.06-58.2%
2024-12-31$-1.56$-1.14+26.9%$6352.00-97.4%
2024-09-30$-1.09$-0.78+28.4%$-6352.00-104.9%
2024-06-30$-1.77$-1.31+26.0%$2342.00
2024-03-31$-0.19$-0.18+5.3%$117029.00
2023-12-31$-0.19$-0.23-21.1%$244812.00
2023-09-30$-0.29$-0.16+44.8%$130440.00

Frequently asked questions

When does Soligenix Inc. report next earnings?
Soligenix Inc. (SNGX) is scheduled to report earnings on December 31, 2025. The consensus EPS estimate is $-0.27.
Has Soligenix Inc. beaten earnings estimates?
Soligenix Inc. has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of -152.7% over the last 3 quarters.
How does SNGX stock react to earnings?
SNGX stock has moved an average of +4.9% in the trading day following earnings over its last 2 reports, with positive reactions in 100% of those quarters.